Details for Patent: 9,675,549

« Back to Dashboard

Which drugs does patent 9,675,549 protect, and when does it expire?

Patent 9,675,549 protects VANFLYTA and is included in one NDA.

This patent has five patent family members in four countries.

Summary for Patent: 9,675,549

Title:	Tablet containing composite with cyclodextrin
Abstract:	Provided herein is a tablet comprising, as a drug, N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof, which is a medicament for treating acute myeloid leukemia (AML), the tablet characterized by comprising a composite of N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof and hydroxypropyl-β-cyclodextrin in a ratio ranging from 1:8 to 1:20.
Inventor(s):	Shinsuke Oba, Hiroyasu Toyota, Satomi Ikeuchi, Takumi Hara, Emiko Murayama, Kei Motonaga
Assignee:	Ambit Bioscience Corp
Application Number:	US14/432,387
Patent Claim Types: see list of patent claims	Composition; Dosage form;

Drugs Protected by US Patent 9,675,549

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Daiichi Sankyo Inc	VANFLYTA	quizartinib dihydrochloride	TABLET;ORAL	216993-001	Jul 20, 2023		RX	Yes	No			Y
Daiichi Sankyo Inc	VANFLYTA	quizartinib dihydrochloride	TABLET;ORAL	216993-002	Jul 20, 2023		RX	Yes	Yes			Y

International Family Members for US Patent 9,675,549

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2903593
Spain	2665868
Japan	2014070061
Japan	6116847
World Intellectual Property Organization (WIPO)	2014055397